Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Kohane

Interventional Pain Medicine Babylon, NY Medical Doctor

NPI 1235399734 CMS profile 192310

500 W Main St, Suite 116, Babylon, NY 11702

Open in the dashboard

General payments

$26,629

1,303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Kohane of Babylon, NY is reported in the CMS Open Payments database as having received $26,629 across 1,303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,047 186
2024 General $9,797 189
2023 General $3,301 203
2022 General $3,182 222
2021 General $3,434 259
2020 General $1,628 110
2019 General $2,241 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kohane
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Daniel Kohane were reported at $3,047. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Daniel Kohane Interventional Pain Medicine median Middle half National median
2019 $2,241 $684 $216–$2,079 $163
2020 $1,628 $382 $122–$1,109 $114
2021 $3,434 $552 $167–$1,554 $132
2022 $3,182 $605 $187–$1,924 $149
2023 $3,301 $671 $195–$1,915 $160
2024 $9,797 $684 $206–$1,837 $164
2025 $3,047 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. International Rehabilitative Sciences, Inc $7,164 1 payment
  2. Collegium Pharmaceutical, Inc. $2,299 392 payments
  3. Boston Scientific Corporation $2,298 126 payments
  4. Abbott Laboratories $1,741 101 payments
  5. AbbVie, Inc. $1,067 57 payments
  6. Relievant Medsystems, Inc. $907 22 payments
  7. Nevro Corp. $897 78 payments
  8. Scilex Pharmaceuticals Inc. $756 40 payments
  9. Forte Bio-Pharma LLC $727 18 payments
  10. Medtronic, Inc. $635 45 payments
  11. Other $8,138 423 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,080 1,297 payments
  2. Long term medical supply or device loan $7,164 1 payment
  3. Travel and Lodging $326 2 payments
  4. Education $58 3 payments
Products named General payments · program years 2019–2025
  1. RS-LBG, RS-FBG $7,164 1 payment
  2. RS 4i Plus Sequential Stimulator $7,164 1 payment
  3. XTAMPZA $1,495 226 payments
  4. Intracept $752 21 payments
  5. BELBUCA $746 153 payments
  6. PROLATE Pain $710 17 payments
  7. PROLATE Pain $710 17 payments
  8. PROLATE Pain $710 17 payments
  9. NALOCET $710 17 payments
  10. QULIPTA $687 37 payments
  11. Other $17,656 930 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,073

Median for Interventional Pain Management: 1,220

Drug cost

$142,366

Median for Interventional Pain Management: $39,344

Branded share of claims

38.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 453 $39,621
Xtampza Er Oxycodone Myristate Brand 47 $31,806
Prolate Oxycodone Hcl/Acetaminophen Brand 19 $13,796
Belbuca Buprenorphine Hcl Brand 16 $11,748
Diclofenac Sodium Generic 60 $7,085
Lidocaine Generic 56 $6,591
Hysingla Er Hydrocodone Bitartrate Brand 15 $5,747
Movantik Naloxegol Oxalate Brand 11 $5,209
Pregabalin Generic 116 $3,516
Fentanyl Generic 18 $3,236

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$321,490

Of which drugs: $16,396

Medicare patients

380

Average age 72

Services billed

6,202

235 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Ischemic heart disease 37%
Depression 28%
COPD 22%
Chronic kidney disease 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 16 936 $12,602
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 1,891 $178
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 106 $77
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 172 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
$255 — —
XTAMPZA
$231 47 —
BELBUCA
$219 16 —
Qutenza
$153 — —
PROLATE
$134 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

1,303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record